{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:50:42Z","timestamp":1773705042730,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Per FDA guidance, method comparability should be established if an anti-drug antibody (ADA) assay is run by two or more independent laboratories during a study. Genentech, Inc. is evaluating an immunogenicity risk-based comparability approach consisting of both technical and clinical aspects. Technical comparability of the relative sensitivity (RS) is assessed using the Two One-Sided T-tests (TOST) statistical analysis which evaluates if the difference (in absolute value) of the RS means of the two laboratories is less than a pre-specified level of comparability, the practically significant difference (PSD). Clinical comparability is based on the molecule\u2019s immunogenicity risk. A basic and in-depth assessment for low and high-risk molecules are used, respectively. An alternative strategy for molecules with limited incurred sample availability is to be used. In the basic assessment, samples are either unfortified or fortified with surrogate ADA positive control at method appropriate concentrations in a representative biological matrix. Acceptable comparability requires in both methods i) at least 80% of the unfortified samples screen and confirm negative, ii)\u00a0at least 90% of the\u00a0low concentration samples screen and confirm positive; and iii) 100% of the high concentration samples screen and confirm positive. The in-depth assessment uses at least 100 incurred samples from 30 or more ADA-positive and ADA-negative patients. The results are evaluated using a 2 by 2-confusion matrix and Cohen\u2019s Kappa score where <jats:bold>1<\/jats:bold> indicates perfect agreement. Acceptable comparability requires a Cohen\u2019s Kappa score of greater than 0.40. This strategy allows for a robust technical and clinical method comparability assessment.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-024-00999-3","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:49:36Z","timestamp":1734637776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bioanalytical Method Comparison Strategy for Clinical Anti-drug Antibody Immunoassays"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-1815","authenticated-orcid":false,"given":"R. J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Pourmohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Webb-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Nijem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Siguenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"3","key":"999_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jpba.2008.12.008","volume":"49","author":"TM Thway","year":"2009","unstructured":"Thway TM, Ma M, Lee J, Sloey B, Yu S, Wang YC, DeSilva B, Graves T. Experimental and statistical approaches in method cross-validation to support pharmacokinetic decisions. J Pharm Biomed Anal. 2009;49(3):613\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2008.12.008.","journal-title":"J Pharm Biomed Anal"},{"key":"999_CR2","unstructured":"Immunogenicity testing of therapeutic protein products-developing and validating assays for anti-drug antibody detection [Internet]. 2019. Available from: https:\/\/www.fda.gov\/media\/119788\/download. Accessed 1 Sep 2023"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/BF0106841","volume":"15","author":"DJ Schuirmann","year":"1987","unstructured":"Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657\u201380. https:\/\/doi.org\/10.1007\/BF0106841.","journal-title":"J Pharmacokinet Biopharm"},{"key":"999_CR4","doi-asserted-by":"publisher","unstructured":"Wellek S. General approaches to the construction of tests for equivalence in the strict sense. ln: Chapman and Hall, editors. Testing statistical hypothesis of equivalence and noninferiority. 2nd ed. New York: CRC Press; 2010;33\u201347 https:\/\/doi.org\/10.1201\/EBK1439808184.","DOI":"10.1201\/EBK1439808184"},{"key":"999_CR5","unstructured":"Immunogenicity assessment for therapeutic protein products [Internet]. 2014. Available from https:\/\/www.fda.gov\/media\/85017\/download. Accessed 1 Sep 2023."},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1208\/s12248-021-00642-5","volume":"23","author":"MA Kroenke","year":"2021","unstructured":"Kroenke MA, Nilton MN, Kumar S, Bame E, White JT. Immunogenicity risk assessment for multi-specific therapeutics. AAPS J. 2021;23:115. https:\/\/doi.org\/10.1208\/s12248-021-00642-5.","journal-title":"AAPS J"},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-020-00447-y","volume":"22","author":"G Sperinde","year":"2020","unstructured":"Sperinde G, Montgomery D, Mytych DT. Clinical immunogenicity risk assessment for a fusion protein. AAPS J. 2020;22:1\u20136. https:\/\/doi.org\/10.1208\/s12248-020-00447-y.","journal-title":"AAPS J"},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-020-0420-0","volume":"22","author":"JR Mora","year":"2020","unstructured":"Mora JR, White JT, DeWall SL. Immunogenicity risk assessment for PEGylated therapeutics. AAPS J. 2020;22:1\u201312. https:\/\/doi.org\/10.1208\/s12248-020-0420-0.","journal-title":"AAPS J"},{"issue":"3","key":"999_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ptj\/85.3.257","volume":"85","author":"J Sim","year":"2005","unstructured":"Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005;85(3):257\u201368. https:\/\/doi.org\/10.1093\/ptj\/85.3.257.","journal-title":"Phys Ther"},{"key":"999_CR10","doi-asserted-by":"publisher","unstructured":"Kulkarni A, Chong D, Batarseh FA. Foundations of data imbalance and solutions for a data democracy. In: Batarseh FA, Yang R, editors. Data Democracy. 1st ed. Cambridge: Academic Press; 2020;83\u2013106. https:\/\/doi.org\/10.1016\/B978-0-12-818366-3.00005-8. Accessed Jan 2024.","DOI":"10.1016\/B978-0-12-818366-3.00005-8"},{"issue":"1","key":"999_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Edu Psycol Meas. 1960;20(1):37\u201346. https:\/\/doi.org\/10.1177\/001316446002000104.","journal-title":"Edu Psycol Meas"},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374. https:\/\/doi.org\/10.2307\/2529310.","journal-title":"Biometrics"},{"issue":"3","key":"999_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic Lesson in biostatistics. Biochemia Medica. 2012;22(3):276\u201382. https:\/\/doi.org\/10.11613\/BM.2012.031.","journal-title":"Biochemia Medica"},{"issue":"2","key":"999_CR14","first-page":"127","volume":"86","author":"DV Cicchetti","year":"1981","unstructured":"Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am J Ment Defic. 1981;86(2):127\u201337.","journal-title":"Am J Ment Defic"},{"key":"999_CR15","doi-asserted-by":"publisher","unstructured":"Fleiss JL, Levin B, Paik MC. The measurement of interrater agreement. ln: Statistical methods for rates and proportions, 3rd edition. ln: Shewart WA, Wilks SS, editors. John Wiley & Sons, Ltd; 2003;598\u2013626. https:\/\/doi.org\/10.1002\/0471445428","DOI":"10.1002\/0471445428"},{"key":"999_CR16","unstructured":"Immunogenicity information in human prescription therapeutic protein and select drug product labeling - content and format [Internet]. draft 2022. Available from https:\/\/www.fda.gov\/media\/155871\/download. Accessed 14 Oct 2024."},{"issue":"2","key":"999_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cei.12742","volume":"184","author":"GR Gunn 3rd","year":"2016","unstructured":"Gunn GR 3rd, Sealey DC, Jamali F, Meibohm B, Ghosh S, Shankar G. From the bench to clinical practice: understanding the challenges and uncertainties for biopharmaceuticals. Clin Exp Immunol. 2016;184(2):137\u201346. https:\/\/doi.org\/10.1111\/cei.12742.","journal-title":"Clin Exp Immunol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00999-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:57:29Z","timestamp":1740506249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00999-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00999-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are all employees of Genentech, Inc. and stockholders of the Roche group. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"19"}}